ACP
TYRA icon

Acuta Capital Partners’s Tyra Biosciences TYRA Stock Holding History

Acuta Capital Partners’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,867
Closed -$123K – 42
2023
Q4 		$123K Buy
+8,867
New +$115K 0.07% 37

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Acuta Capital Partners's TYRA Position: Q1 2024 in Review

Acuta Capital Partners sold out of Tyra Biosciences (TYRA) in Q1 2024, closing a stake of 8,867 shares — an estimated $123K sold.

Acuta Capital Partners first reported a position in TYRA in Q4 2023 and held it in 1 quarter. The position peaked at $123K in Q4 2023. 77 funds tracked by Wall St. Rank hold TYRA as of Q1 2024.

  • Acuta Capital Partners reported no remaining Tyra Biosciences position as of Q1 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 8,867 Tyra Biosciences shares in Q1 2024, an estimated $123K.
  • Acuta Capital Partners first reported a position in Tyra Biosciences in Q4 2023 and held it in 1 quarter.
  • Acuta Capital Partners's Tyra Biosciences position peaked at $123K in Q4 2023.
  • 77 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2024.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.